I believe Abiraterone's bigger opportunity is as an option for chemo/biologic naive patients who fail anti-androgens in other words as a second-line hormone therapy (#msg-55413563).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.